Number of residual nodules, better than size, defines optimal surgery in advanced epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 14, Issue 5, 2004, Pages 779-787

  Stoeckle, E ^a   Paravis, P ^a   Floquet, A ^a   Thomas, L ^a   De Lara, C Tunon ^a   Bussieres E ^a   MacGrogan, G ^a   Picot, V ^b   Avril, A ^a  

^a INSTITUT BERGONIÉ   (France)

^b Regional Cancer Centre ^*

Author keywords

Number; Optimal surgery; Ovarian cancer; Residual nodules; Size

Indexed keywords

CISPLATIN;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ANALYTIC METHOD; ARTICLE; ASCITES; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; FACTORIAL ANALYSIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; OVARY CANCER; PERITONEUM; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; QUALITATIVE ANALYSIS; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE; SURVIVAL TIME; TUMOR VOLUME;

ADOLESCENT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PATIENT CARE PLANNING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 4544288669     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1048-891X.2004.014508.x     Document Type: Article

References (18)

1. Griffiths CT, Fuller AF. Intensive surgical and chemotherapeutic management of advanced ovarian cancer. Surg Clin North Am 1978;58:131-42.
2. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-59.
3. Heintz APM, Van Oosterom AT, Trimbos JBMC, Schaberg A, Van der Velde EA, Nooy M. The treatment of advanced ovarian adenocarcinoma (I): clinical variables associated with prognosis. Gynecol Oncol 1988;30:347-58.
4. Hoskins WJ, Rubin S. Surgery in the treatment of patients with advanced ovarian cancer. Semin Oncol 1991;18:213-21.
5. Eisenkop SM, Nalick RH, Wang H, Teng NH. Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: impact on survival. Gynecol Oncol 1993;51:224-9.
6. Farias-Eisner R, Teng F, Oliveira M et al. The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery. Gynecol Oncol 1994;55:108-10.
7. Vergote I, de Wever I, Tjamal W, van Gramberen M, Decloedt J, van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 1998;71:431-6.
8. Thomas L, Pigneux J, Chauvergne J et al. Evaluation of whole abdominal irradiation in ovarian carcinoma with a four field technique. Int J Radiat Oncol Biol Phys 1994;30:1083-90.
9. Stöckle E, Chauvergne J, Pigneux J et al. Evolution à long terme après seconde laparotomie dans les cancers de l'ovaire. Bull Cancer 1990;77:1087-98.
10. Stöckle E, Bussières E, Stöckle M et al. Que reste-t-il de la laparotomie de deuxième vue dans le traitement des cancers de l'ovaire? Bull Cancer 1993;80:629-38.
11. Omura G, Blessing J, Ehrlich C et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatine in advanced ovarian carcinoma. Cancer 1986;57:1725-30.
12. Le T, Krepart GV, Lotocki RJ, Heywood MS. Does debulking surgery improve survival in biologically aggressive ovarian carcinoma? Gynecol Oncol 1997;67: 208-14.
13. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 1998;69:103-8.
14. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47:159-66.
15. Neijt JP, ten Bokkel Huinink WW, Van der Burg ME et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-T v CP) in advanced ovarian carcinoma. J Clin Oncol 1997;5:1157-68.
16. Potter ME, Partridge EE, Hatch KD, Soong S, Austin JM, Shingleton HM. Primary surgical therapy of ovarian cancer: how much and when? Gynecol Oncol 1991;40: 195-200.
17. Omura GA, Brady MF, Homesley HD et al. Long follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991;9:1138-50.
18. Hoskins WJ, McGuire WP, Brady MF et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974-80.